Ketamine-related expression of glutamatergic postsynaptic density genes: Possible implications in psychosis

https://doi.org/10.1016/j.neulet.2007.01.041Get rights and content

Abstract

Systemic administration of ketamine, a non-competitive antagonist of the N-methyl-d-aspartate receptor (NMDA-R), produces a condition of NMDA-R hypofunction, which is considered one of the putative molecular mechanisms involved in psychosis. In this study, we evaluated the effect of ketamine on glutamatergic markers of the postsynaptic density (PSD), a pivotal site for dopamine–glutamate interaction. We assessed gene expression of Homer1a, α and βCaMKII, and dopamine transporter (DAT) by two different doses of ketamine. These genes were chosen because of their impact on signal transduction and dopamine–glutamate interplay in postsynaptic density. Moreover, Homer1a is modulated by antipsychotics and represents a candidate gene for schizophrenia. Male Sprague–Dawley rats were injected with saline, 12 mg/kg ketamine or 50 mg/kg ketamine, and sacrificed 90 minutes after injections. In situ hybridization histochemistry was used to quantitate the rate of gene expression in rat forebrain. Homer1a was induced by 50 mg/kg ketamine in ventral striatum and by both 50 and 12 mg/kg ketamine in nucleus accumbens, whereas gene expression was not affected in dorsal striatum. αCaMKII was increased by 12 mg/kg ketamine against saline in almost all subregions assessed. βCaMKII was not affected by ketamine. DAT was increased by both doses of ketamine in the ventro-tegmental area and substantia nigra pars compacta. We suggest that these changes may represent molecular adaptations to the perturbation in glutamatergic transmission induced by ketamine blockade of NMDA receptors and may be implicated in molecular alterations occurring in schizophrenia.

References (38)

  • J.W. Olney et al.

    NMDA receptor hypofunction model of schizophrenia

    J. Psychiatry Res.

    (1999)
  • Y. Pan et al.

    Striatal cell signaling in chronically food-restricted rats under basal conditions and in response to brief handling

    Neurosci. Lett.

    (2006)
  • M.L. Wadenberg et al.

    Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects

    Neuropsychopharmacology

    (2001)
  • B.H. Westerink et al.

    Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum

    Eur. J. Pharmacol.

    (2001)
  • M. Yano et al.

    Inhibition of methylphenidate-induced gene expression in the striatum by local blockade of D1 dopamine receptors: interhemispheric effects

    Neuroscience

    (2006)
  • Y. Yoshimura et al.

    Identification of protein substrates of Ca(2+)/calmodulin-dependent protein kinase II in the postsynaptic density by protein sequencing and mass spectrometry

    Biochem. Biophys. Res. Commun.

    (2002)
  • B. Adams et al.

    Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine

    J. Neurosci.

    (1998)
  • A. Anand et al.

    Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists

    Arch. Gen. Psychiatry

    (2000)
  • P.R. Brakeman et al.

    Homer: a protein that selectively binds metabotropic glutamate receptors

    Nature

    (1997)
  • Cited by (42)

    • Ultrastructural evidence for glutamatergic dysregulation in schizophrenia

      2022, Schizophrenia Research
      Citation Excerpt :

      This is consistent with our vGLUT2 findings and in the synaptic data in the dorsal striatum described above. In agreement with this finding is evidence for an increased expression of excitatory postsynaptic density proteins after ketamine stimulation and in the NAcc in postmortem schizophrenia (Kajimoto et al., 2003; Iasevoli et al., 2007). Rodent models of schizophrenia also exhibit increased indices of glutamatergic-type input in the NAcc.

    • Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia

      2019, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      The non-competitive NMDA-R antagonist PCP has been shown to restore normal levels of Homer1a in the PFC in D-aspartate-oxidase KO mice which have lower basal level of expression than wild-type (WT) mice (de Bartolomeis et al., 2015c), as well as it has been shown to modulate Homer1a mRNA within the prefrontal, primary auditory, and retrosplenial cortices in a time-dependent manner (Cochran et al., 2002). Similarly, ketamine enables Homer1a transcription in the rat ventral striatum (Iasevoli et al., 2007). Homer1a has been found to be instrumental for antidepressant mechanism in KO A1adenosine mouse model of depression (Serchov et al., 2015).

    • The Acute and Chronic Effects of Ketamine as Revealed by Noninvasive Brain Imaging

      2016, Neuropathology of Drug Addictions and Substance Misuse
    View all citing articles on Scopus
    View full text